A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non ...

Gilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.

Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, ...

Are you looking for nutrients to support your brain health? Choline can make an impactful difference, so discover 13 ...

NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...

Perioperative chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC) shows promising long-term benefits with ...

Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...

The CFTR protein reaches the cell membrane but the channel does not ... or placebo for 28 days Part 1 Group 1 (n = 4) VX-770 25 mg twice daily, then VX-770 75 mg twice daily Group 2 (n = 4 ...

The following is a summary of “Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year ...

“We are proud of the progress made in the third quarter of 2024 to advance our investigational allogeneic cell products in key “firsts ... of ALLO-316 following standard FC (fludarabine (30 mg/m2) and ...

Absci has a long and expensive path to traverse before it can prove the merits of its approach though. Its cash burn is ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...